I need to tell you something I never said in fourteen years of pharmaceutical sales.

Not because I was prohibited from saying it. Because I genuinely did not know it.

That distinction matters to me. But I am not certain it would have mattered much to the patients sitting in the waiting rooms of every nephrologist I visited across the country for over a decade, watching their quarterly number fall while their doctors prescribed the exact medications I had spent the morning presenting over coffee.

I was a pharmaceutical sales representative for fourteen years. Cardiovascular and renal division. I called on roughly two hundred nephrologists across the UK. I knew the clinical trial data on ACE inhibitors better than most GPs. I could present the mechanism of ARBs in my sleep. I attended nephrology conferences. I read the study abstracts. I bought the coffees and the sandwiches and I sat across from doctors who trusted that I was bringing them the most current clinical picture.

I retired at fifty. I had planned to take six months off before deciding what to do next.

I spent those six months finding out what my sales training had never included.

The Day I Cleared Out My Home Office

Three months into retirement I was clearing out the filing cabinet in my home office. The one that had followed me through five company cars and twelve territory changes.

I found my original sales training materials. The laminated product cards. The mechanism slide decks. The approved scripts for handling objections.

I sat on the floor of my study and read through them the way I had never read them before.

Not as a representative building her quarterly numbers.

As a patient.

Because six weeks earlier, at a routine private health check I had booked out of habit, my creatinine had come back elevated. My eGFR was 54. The doctor had said: “Stage 3a. We'll monitor it. Worth seeing a nephrologist.”

I had nodded in the way I had watched thousands of patients nod across conference room tables when I presented slides showing that ramipril slowed the rate of decline.

Slowed.

Not stopped.

Sitting on that floor, reading the mechanism slides I had presented hundreds of times, I noticed something I had never noticed in fourteen years.

Every drug in my portfolio managed the problem from outside the kidney cells.

Not one of them was designed to address what was happening inside.

I had never asked why. Because nobody had ever given me a reason to ask.

What 14 Years of Pharmaceutical Sales Actually Taught Me — And What It Didn't

I want to be precise about what the medications I sold actually do. Because they are not wrong. They are genuinely important and genuinely effective at what they were designed to address.

ACE inhibitors reduce haemodynamic pressure inside the glomerular capillaries. This is real. This matters. It slows the rate at which mechanical filtration pressure damages the kidney's filtration structures.

ARBs do the same through a complementary pathway. Blocking the angiotensin receptor. Reducing the pressure. Protecting the vessel walls. My best product had a study showing a 28 percent reduction in the rate of proteinuria progression. I presented that slide in two hundred consultation rooms.

In fourteen years of selling these products, not one training session, not one medical affairs briefing, not one conference symposium ever explained what was happening inside the kidney cells themselves that none of these interventions was designed to address.

I did not know there was a gap.

I had been trained to sell what was in the gap's shadow so thoroughly that I had never thought to look at the gap itself.

What I Found When I Started Reading Without A Quarterly Target

The research was not difficult to find. It was available on PubMed. I had a PubMed account. I had used it to pull study abstracts for fourteen years.

What I had never done was follow a single line of evidence to its conclusion without a sales objective waiting at the end of it.

Inside the nephron cells — the actual filtration units — filtration generates reactive oxygen species continuously. Hydroxyl radicals specifically. The most destructive free radicals the body produces.

In healthy kidneys, cellular antioxidant enzymes neutralise these radicals almost instantly. In kidneys with CKD, that neutralisation capacity is overwhelmed. The radicals accumulate. They attack the mitochondrial membranes from within. They trigger fibrotic signalling — the process that converts healthy filtration tissue into permanent scar tissue.

The scar tissue restricts blood supply to the healthy nephrons around it. Those nephrons die. More radicals form from the damaged filtration cycles of the remaining nephrons. The cascade accelerates.

Every single hour. In every CKD patient. Completely independently of blood pressure. Completely independently of protein intake. Completely independently of every drug in every portfolio I had carried for fourteen years.

I sat at my kitchen table and thought about the mechanism slides I had laminated and presented two hundred times.

They were accurate. Every word.

They simply described what the drugs did. Not what they left running.

Then I found the Osaka University Hospital study from 2019.

CKD patients in Japan on standard treatment declining at 1.3 eGFR points per year. Western patients on identical medications declining at 4.2. Thirty-four percent of Japanese patients showing actual improvement.

The difference was molecular hydrogen therapy. H₂. The smallest molecule in existence. Small enough to cross cell membranes without any transport system — directly into the nephron cells, directly to the mitochondria, where it neutralises the hydroxyl radicals at the precise point where the cascade begins.

Over 400 Japanese hospitals had been using this as standard nephrology protocol for years.

I called my former regional medical affairs manager. I had worked with him for six years.

I asked him if our team had ever been briefed on molecular hydrogen therapy.

He was quiet for a moment.

“There's no margin in water, Lisa. You know how this works.”

I did know how it worked. I had worked inside it for fourteen years. I simply had not understood what it was leaving out.

What I Did Next

My eGFR at that first health check had been 54. By the time I finished reading the Osaka study it had dropped to 49 at my three-month follow-up. My new nephrologist — a kind man, thorough — used the words I had heard in so many consultation rooms over so many years.

“Progressive decline is expected at this stage. We'll continue to monitor.”

I heard those words differently now.

I ordered a Pryxo™ device that evening. Medical-grade stainless steel. Platinum-coated electrolysis chamber — the same electrode technology the Japanese hospital protocols specify. Verified output at 1.5 parts per million — the exact concentration the clinical trials used, confirmed by third-party certificate of analysis. On-demand fresh production, because hydrogen dissipates within hours and pre-bottled products lose their concentration before consumption.

The same specification. For home use.

I also contacted my former manager again. And sent him the research.

He has not responded.

What Happened When I Actually Used It

I want to be precise. I spent fourteen years presenting clinical data. I know what documentation looks like and I know what anecdote looks like. What follows is documentation.

Week One

The metallic taste I had been waking up with every morning for four months disappeared. I had been attributing it to my ramipril. It is a documented symptom of the oxidative cascade running at the cellular level. Its disappearance in week one was confirmation that the hydrogen was crossing into the cells where the damage was occurring.

Week Two

My husband said I seemed like I had more energy. I had been attributing my afternoon fatigue to the psychological adjustment of leaving a high-pace career. He noticed it before I did.

Week Three

The ankle swelling I had been noting quietly every evening — attributing it to long days on my feet visiting practices — reduced noticeably. I pressed the tissue. It responded normally. I had not seen that in months.

Week Four

I slept through the night. I had been waking at three in the morning with the specific anxiety of someone calculating timelines. The night I slept through I lay there for a moment in the morning registering its absence.

Month Three

I had my quarterly bloods drawn. My nephrologist opened the results at the appointment.

He looked at the screen for longer than usual. Clicked back through the previous quarters.

“Lisa. Your eGFR is 58. Up from 49.”

I said: say that again.

“Nine points. In one quarter. And your proteinuria markers have dropped by 37 percent.”

He turned the screen toward me.

“This is not consistent with the trajectory I was expecting. What changed?”

I told him everything. The mechanism. The oxidative cascade that runs inside the cells that none of the drugs I had sold for fourteen years was designed to reach. The Osaka data. The concentration. The device.

He typed notes.

“The oxidative stress mechanism in CKD progression is well-supported in the literature. It doesn't appear in standard guidelines because there is no pharmacological pathway for molecular hydrogen.” He paused. “But these numbers represent a meaningful and unexpected reversal.”

He closed the file.

“Keep doing whatever you are doing.”

I Wish I Had Known This When I Was Still Selling. I Cannot Go Back. But You Are Reading This Now.

I spent fourteen years in consultation rooms presenting the best available pharmaceutical evidence to nephrologists who trusted that I was giving them the complete picture.

I was giving them the picture that had been assembled by commercially-funded research. That is a different thing. And the difference between those two pictures represents a gap that I carried into two hundred consultation rooms without ever knowing it was there.

The drugs I sold are not wrong. Your ACE inhibitor is doing something real and necessary. Your ARB, your ramipril, your irbesartan — they are addressing real mechanisms and they should not be stopped.

But they were never designed to reach the oxidative cascade running inside your nephron cells. Nobody briefed me on that gap for fourteen years. I am telling you now.

Pryxo™ addresses the mechanism the rest of your treatment was never built to reach. The research behind it has been sitting in peer-reviewed journals for over a decade. Four hundred Japanese hospitals have been using it as standard care. The reason your nephrologist has never mentioned it is the same reason I never mentioned it in fourteen years of sales calls — not because it does not work, but because the commercial infrastructure that funds guidelines had no revenue model for a molecule that dissolves in water.

You now know what fourteen years in pharmaceutical sales never taught me.

Where To Get It

Pryxo™ does not sell through pharmacies or major retailers. You order directly. I was initially uncertain about that — and then I understood it is how they maintain the manufacturing standard the clinical specification requires.

There is a 90-day money-back guarantee. If your next quarterly blood test shows no movement, full refund. No questions asked. The risk is entirely theirs.

It is a one-time purchase. Not a subscription. Less than most people spend in a month on supplements that were never going to reach the cells they were supposed to help.

I cannot give back the years or the consultation rooms. But I can tell you what my sales training never included.

This is what I found.